Oct '07 - Jonathan Kinlay Speaking at Hedge Fund Replication & Alternative Beta Conference in NY

Proteom CEO Jonathan Kinlay will be participating ina panel discussion on replication strategies at the upcoming conference in New York this fall.

June '07 - Jonathan Kinlay Speaking at GAIM Conference Monte Carlo

Proteom CEO Jonathan Kinlay presented Proteom's equity statistical arbitrage strategy to investors at this year's European GAIM conference.

June '07 - Jonathan Kinlay Speaking at Battle of the Quants Conference London

Proteom CEO Jonathan Kinlay chaired a session on hedge fund replication at the London BOTQ conference.

April '07 - Jonathan Kinlay Speaking at Hedge Fund Incubation Conference New York

Proteom CEO Jonathan Kinlay participated in a panel forum on hedge fund incubation at this year's conference in New York.

Feb '07 - Jonathan Kinlay Speaking at Managed Account Conference New York

Proteom CEO Jonathan Kinlay participated in a panel forum on hedge fund managed accounts at this year's conference in New York.

May '06 - Jonathan Kinlay Speaking at Hedge Fund Quant Conference Bermuda

Proteom CEO Jonathan Kinlay spoke at the conference on Quant hedge fund strategies in Bermuda in May 2006.

Oct '05 - Proteom Features in Banker Magazine Article on Algorithmic Trading

Proteom CEO is quoted in the October issue of Banker magazine article "Into Battle with the Algorithmic Traders".

Read article.

15 Nov '04 - Proteom Announces Long Volatility Fund

The Bermudan-based Proteom Fund today announced that it is to offer a new long volatility product designed to produce substantial gains of 10%-25% during market crashes, while continuing to offer moderate returns of 5% - 7% under normal market conditions. The strategy is negatively correlated with the market and can be used for yield enhancement and hedging purposes either on a stand alone basis or as an overlay to existing long/short equity strategies. Proteom offers a number of equity long/short, market neutral and volatility arbitrage strategies based on the research in econometrics and bio-sciences of the Fund’s founders, econometrician Jonathan Kinlay and bio-statistician Haftan Eckholdt.

Read press release.

11 Aug '04 - Proteom Launch in Hedge Fund Alert

Jonathan Kinlay, whose Caissa Capital Partners just shut down the U.S. version of his volatility-arbitrage fund, is aiming for Sept. 1 to launch an equity vehicle that will rely on gene-sequencing technology to select investments. Kinlay’s newly founded Proteom Capital Management of Bermuda expects to launch its Proteom Fund with $10 million to $25 million. The firm’s computer programs utilize software that was originally developed to find patterns in massive amounts of biological data — such as the information used for gene sequencing — to identify investments in S&P 500 stocks.

Read article.